Compare Pfizer Inc (PFE) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Pfizer Inc trades at $27.75 (market cap $159.59B), while Vanguard Ultra Short Bond ETF trades at $49.47 (market cap $10.20B). The key difference: Pfizer Inc is far larger — about 15.6× Vanguard Ultra Short Bond ETF's market cap, and Pfizer Inc pays a 6.14% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Ultra Short Bond ETF for 61 Days on average.
| PFE | VUSB | |
|---|---|---|
Market Cap | $159.59B | $10.20B |
Volume | 30,937,010 | 3,032,339 |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.02 | $50.03 |
52-Week Low | $23.67 | $49.41 |
Typical Hold Time | 158 Days | 61 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
VUSB trades at $49.48, up 0.08% with minimal daily movement. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $50 and support at $49. Recent news highlights potential benefits from short-term bond strategies amid Federal Reserve rate uncertainty.
The outlook remains cautious due to bearish technical signals and interest rate sensitivity. Opportunities include dividend stability with recent payouts, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term bond appeal against broader economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
